Surrogate end points as a clinical and public health problem. The cerivastatin case

Medicina Clinica

Volumn 119, Issue 7, 2002, Pages 254-259

  Gérvas, Juan ^a   Pérez Fernández, Mercedes ^a  

^a NONE   (Spain)

Author keywords

Cardiovascular risks; Cerivastatin; Clinical trials; Medical decision making; Statins; Surrogate end points

Indexed keywords

ANTACID AGENT; ANTICOAGULANT AGENT; CERIVASTATIN; CIMETIDINE; DIGOXIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRAVASTATIN; SIMVASTATIN; WARFARIN; BIOLOGICAL MARKER; PYRIDINE DERIVATIVE;

ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE MARKER; DRUG EFFICACY; DRUG SAFETY; HEALTH HAZARD; HUMAN; HYPERCHOLESTEROLEMIA; PUBLIC HEALTH; RISK; TREATMENT OUTCOME;

BIOLOGICAL MARKERS; CLINICAL TRIALS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; PYRIDINES; RISK; TREATMENT OUTCOME;

EID: 0037037265     PISSN: 00257753     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0025-7753(02)73379-4     Document Type: Article

References (75)

1. Smith R. The ethics of ignorance. J Med Ethics 1992;18:117-8, 134.
2. Pocock ST, Elbourne DR. Randomized trials or observational tribulations? N Engl J Med 2000;342:1907-9.
3. Bucker HC, Guyatt GH, Cook DJ, Holbrook A, McAlister FA. Users' guides to the medical literature. XIX Applying clinical trials results. A. How to use an article measuring the effect of an intervention on surrogate end points. JAMA 1999;282:771-8.
4. Psaty BM, Weiss NS, Furberg CD, Koepsell TD, Siscovick DS, Rosendaal FR, et al. Surrogate end points, health outcomes, and the drug-approval process for the treatment of risk factors for cardiovascular disease. JAMA 1999;282:786-90.
5. McAlister FA, Laupacis A, Wells GA, Sackett DL. Users' guide to the medical literature. XIX Applying clinical trial results. B. Guidelines for determining whether a drug is exerting (more than) a class effect. JAMA 1999;282:1371-7.
6. Greene WL, Concato J, Feinstein AR. Claims of equivalence in medical research: are they supported by the evidence? Ann Intern Med 2000;132:715-22.
7. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
8. Carter BL. Blood pressure as a surrogate end point for hypertension. Ann Pharmacother 2002;36:87-92.
9. Grossman E. Meserli FH, Grodzicki T, Kowey P. Should a moratorium be placed on sublingual nifedipine capsules given for hypertensive emergencies and pseudoemergencies. JAMA 1996;276:1328-31.
10. Messerli FH, Grossman E. The use of sublingual nifedipine. Arch Intern Med 1999;159:2259-2260
11. Furgerg CD, Pitt B. Withdrawal of cerivastatin from the world market. Curr Control Trials Cardiovascular Med 2001;2:205-7.
12. Stein E, Sprecher D, Allenby KS, Tosiello RL, Whalen E, Ripa SR. Cerivastatin, a new potent synthetic HMG-CoA reductase inhibitor: effect of 0,2 mg daily in subjects with primary hypercholesterolemia. J Cardiovasc Pharmacol Ther 1997;2:7-16.
13. Sasaki J, Arawaka K, Yamamoto K, Kobori S, Ageta M, Kono S. A long-term comparative trial of cerivastatin sodium, a new HMG-CoA reductasa inhibitor, in patients with primary hypercholesterolemia. Clin Ther 1998;20:539-48.
14. Stein E. Cerivastatin in primary hiperlipemia. A multicenter analysis of efficacy and safety. Atherosclerosis 1998;139 (Suppl 1):15-22.
15. Farnier M. Cerivastatin in the treatment of mixed hiperlipemia: the RIGHT study. Am J Cardiol 1998;82 (Suppl 4B): 47-51.
16. Rubinstein A, Maritz FJ, Soule SG, Markel A, Chajek-Shaul T, Maislos M, et al. Efficacy and safety of cerivastatin for type 2 diabetes and hypercholesterolaemia. J Cardiovasc Risk 1999;6:399-403.
17. Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B. Efficacy and safety of cerivastatin, 0,2 mg and 0,4 mg, in patients with primary hypercholesterolaemia: a multinational, randomized, double blind study. Curr Med Res Opin 1999;15:228-40.
18. Betteridge DJ. International multicentre comparison of cerivastatin with placebo and simvastatin for the treatment of patients with primary hypercholesterolaemia. Int J Clin Pract 1999;53:243-50.
19. Leiter LA, Hanna K. Efficacy and safety of cerivastatin in primary hypercholesterolemia: a long term comparative titration study with simvastatin. Can J Cardiol 1999;15:545-55.
20. Hanefeld M, Deslypere JP, Ose L, Durrington PN, Farnier M, Schmage N. Efficacy and safety of 300 micrograms and 400 micrograms cerivastatin once daily in patients with primary hypercholesterolaemia: a multicentre, randomized, double-bind, placebo-controlled study. J Int Med Res 1999;27:115-29.
21. Stein E, Isaacsohn J, Stolz R, Mazzu A, Liu MC, Lane C, et al. Pharmacodynamics, safety, tolerability, and pharmacokinetics of the -0,8 mg dose of cerivastatin in patients with primary hypercholesterolemia. Am J Cardiol 1999;83:1433-6.
22. Dujovne CA, Knopp R, Kwiterovich P, Hunninghake D, McBride TA, Poland M. Randomized comparison of the efficacy and safety of cerivastatin and pravastatin in 1030 hypercholesterolemic patients. Mayo Clin Proc 2000;75:1124-32.
23. Saunders E, Ferdinand K, Yellen LG, Tonkon MJ, Krug-Gourley S, Oland M. Efficacy and safety of cerivastatin and pravastatin in the treatment of primary hypercholesterolemia. J Natl Med Assoc 2000;92:319-26.
24. Insull W, Isaacsohn J, Kwiterovich P, Ra P, Brazg R, Dujovne S, et al. Efficacy and safety of cerivastatin 0,8 mg in patients with hypercholesterolaemia: the pivotal placebo-controlled clinical trial. J Int Med Res 2000;28:47-68
25. Renders L, Mayer I, Koch C, Schärffe S, Burkhardt K, Veelken R, et al. Efficacy and drug interactions of the new HMG-CoA reductasa inhibitors cerivastatin and atorvastatin in CsA-treated renal transplant recipients. Nephrol Dial Transplant 2001;16:141-6.
26. McPherson R, Hanna K, Agro A, Braeken A. Cerivastatin versus branded pravastatin in the treatment of primary hypercholesterolemia in primary care practice in Canada: a one-year, open-label, randomized, comparative study of efficacy, safety, and cost-effectiveness. Clin Ther 2001;23: 1492-507.
27. Isaacsohn J, Insull W, Stein E, Kwiterovich P, Patrick MA, Brazg R, et al. Long-term efficacy and safety of cerivastatin 0,8 mg in patients with primary hypercholesterolemia. Clin Cardiol 2001; 24 (9 Suppl):1-9.
28. Hunninghake D, Insull W, Knopp R, Davidson M, Lohrbauer L, Jones P, et al. Comparison of the efficacy of atorvastatin versus cerivastatin in primary hypercholesterolemia. Am J Cardiol 2001;88:635-9.
29. John S, Delles C, Schlaich MP, Schneider M, Schmitz G, Schmieder RE. Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001;37:1351-8.
30. Breuer HW. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Curr Med Res Opin 2001;17:60-73.
31. DeLuis DA, Romero E, Aller R, Izaola O. Effect of cerivastatin on serum cholesterol levels in patients with type 2 diabetes mellitus. Clin Nutr 2000;19:367-70.
32. Ose L, Luurila O, Eriksson J, Olsson A, Lithell H, Widgren B. Cerivastatin gender effect: sub-analyses of results from a multinational, randomized, double-blind study. Curr Med Res Opin 2000;16:80-7.
33. Kelly J, Rudd A. Statins for stroke should be considered in biologically fit people over 75. BMJ 2000;320:1278.
34. Plosker GL, Dunn CI, Figgit DP. Cerivastatin: a review of its pharmacological properties and therapeutic efficacy in the management of hypercholesterolaemia. Drugs 2000;60:1179-206.
35. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation 1995;91:2274-82.
36. Gérvas J, Pérez Fernández M. Las hiperlipemias y la prevención primaria de la cardiopatia isquémica. Med Clin (Barc) 1997;109:549-52.
37. Anónimo. Prescripción de nuevos medicamentos. Bol Ter Andal 2001;17:17-8.
38. Anónimo. Cérivastatine. Une statine, sans plus. Rev Presc 1998;18:806-8.
39. Anónimo. Cerivastatina: insuficiente experiencia clínica. Ficha Novedad Ter (CADIME) 1998;4:1-3.
40. Anónimo. Cerivastatina para la hipercolesterolemia. Med Letter 1998; 20:27-8.
41. Cuesta MT, Martinez M. Nuevos principios activos. Cerivastatina. Inf Ter Sist Nac Salud 1998;22:148-9.
42. Temple R. Are surrogate markers adequate to assess cardiovascular disease drugs? JAMA 1999;282:790-5.
43. Farmer JA. Learning from the cerivastatin experience. Lancet 2001; 358: 1383-1385.
44. Anónimo. Microdosis: la nueva aportación de cerivastatina en el tratamiento de las dislipemias. XXXIV Congreso Nacional de la Sociedad Española de Cardiología [publirreportaje]. Aten Primaria 1998;22:546c.
45. Anónimo. Cerivastatina: reflexiones sobre una retirada. Bull Groc 2001; 14:13-5.
46. Soto S, Mateo C, Abánades JC. Hipercolesterolemia: a quién, cuándo y con qué tratar. Notas Farmacoterapéuticas 1999;6:1-6.
47. Anónimo. Statin therapy. What now? Drug Ter Bull 2001;39:17-21.
48. Anónimo. Seguridad de las estatinas. Eskualdeko Farm Inf 2001;9:40-3.
49. Vila JA, Arnés MC, Navas V, Saa M. Indicaciones terapéuticas y rigor cientifico. SEMERGEN 1999;25:839-40.
50. Anónimo. Grupos terapéuticos y principios activos de mayor consumo en el Sistema Nacional de Salud. Inf Ter Sist Nac Salud 2001;25:78-82.
51. Anónimo. Cerivastatina y rabdomiólisis. Alerta Farmacovigilancia (CADIME) 2001;25:15-6.
52. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107.
53. Anónimo. Suspensión temporal de la comercialización de cerivastatina. Panorama Actual Med 2001;25:598-603.
54. Hamilton-Craig I. Statin-associated myopathy. MJA 2001;175:486-9.
55. Kurata T, Kurata M, Okada T. Cerivastatin induces carotid artery plaque stabilization independently of cholesterol lowering in patients with hypercholesterolaemia. J Int Med Res 2001;29:329-34.
56. Sata M, Nishimatsu H, Suzuki E, Sugiura S, Yoshizumi M, Ouchi Y, et al. Endothelial nitric acid oxide synthase is essential for the HMG-CoA reductase inhibitor cerivastatin to promote collateral growth in response to ischemia. FASEB J 2001;15:2530-2.
57. Tsunekawa T, Hayashi T, Kano H, Sumi D, Matsui H, Thakur NK, et al. Cerivastatin, a hydroxymethylglutaryl coenzyme A reductasa inhibitor, improves endothelial function in elderly diabetic patients within 3 days. Circulation 2001;104:376-9.
58. Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3.
59. González-Fernández F, Jiménez A, López-Blaya A, Velasco S, Arriero MM, Celdaran A, et al. Cerivastatin prevents tumor necrosis factor alpha induced downregulation of endothelial nitric oxide synthase: a role of endothelial cytosolic proteins. Atherosclerosis 2001;155: 61-70.
60. Orezova IN, Jeevan DM, Serdyuk AP, Paramonova IV, Akhmedzhanov NM, Metelskaya VA, et al. Cerivastatin modulates antiatherogenic properties of high-density lipoproteins in patients with coronary heart disease and hyperlipidemia. Bull Exp Biol Med 2000; 130:983-5.
61. Savoie I, Kazanjian A, Bassett K. Do clinical practice guidelines reflect research evidence? J Health Services Res Policy 2000;5:76-82.
62. Fairhurst K, Huby G. From trial data to practical knowledge: qualitative study of how general practitioners have accessed and used evidence about statin drugs in their management of hypercholesterolaemia. BMJ 1998;317:1130-4.
63. Capellà D, Bosh M. Estatinas, ¿beneficio o riesgo? Med Clin (Barc) 2002;118:335-6.
64. CAT. Cerivastatin withdrawn from market. Am J Health Syst Pharm 2001;58:1685.
65. Arriba JJ, Gómez E, Sáez JA, Sáez L. Rabdomiólisis grave asociada a cerivastatina y gemfibrocilo. Med Clin (Barc) 2001;117:278-9.
66. Vilaseca J, Buxeda C, Cámara C, Flor F, Pérez R, Sánchez M. ¿Tienen riesgo coronario los pacientes que tratamos con hipolipemiantes? Aten Primaria 1997;20:49-53.
67. Bonet S, Garcia I, Tomás P, Tapia I, Gussinyé P, Mundet X, ¿Cuándo y cómo tratamos a nuestros pacientes hipercolesterémicos? Aten Primaria 1999;24:397-403.
68. Alegre EJ, Martinez L, Tejedor I, Rabadán A. Asistencia farmacéutica a la prescripción para aproximar la práctica clinica a la evidencia cientifica. Aten Primaria 2001;27:663-6.
69. Silva LC. Hacia una cultura epidemiológica revitalizada. Dimens Hum 1997;1:23-33.
70. Miguel F. Factores de riesgo: una nada inocente ambigüedad en el corazón de la medicina actual. Aten Primaria 1998;22:585-95.
71. Smith GD. Reflection on the limitations to epidemiology. J Clin Epidemiol 2001;54:325-31.
72. Lalonde L, Clarke AE, Joseph L, Mackenzie T, Grover SA. Health related quality of life with coronary heart disease prevention and treatment. J Clin Epidemiol 2001;54:1011-8.
73. Reventlow S, Hvas AC, Tulinius C. «In really great danger...». The concept of risk in general practice. Scand J Prim Health Care 2001;19:71-5.
74. Omar M, Wilson JP, FDA adverse event reports on statin associated rhabdomyolysis. Ann Pharmacother 2002;36:288-95.
75. Staffa JA, Chang J, Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med 2002;346:539-40.